Hydroxychloroquine
K |
|||
(19 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
Zeile 1: | Zeile 1: | ||
+ | {{up|PHA retargeted compounds}} | ||
+ | {{qt|POL HCQ ethics }} | ||
+ | {{qt|Hydroxychloroquine and QTc}} | ||
+ | {{qt|Azithromycin}} | ||
+ | ---- | ||
+ | includes azithromycin + hcq regimes | ||
+ | ---- | ||
+ | |||
+ | |||
+ | |||
+ | {{ttp|p=20436917|t=2010. Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication |pdf=|usr=}} | ||
*check retina status; monitor rhythm known toxicity | *check retina status; monitor rhythm known toxicity | ||
*[https://justthenews.com/politics-policy/coronavirus/doctors-find-hydroxychloroquin-success-rate-91-urge-arizona-maybe-make 91% benefit] | *[https://justthenews.com/politics-policy/coronavirus/doctors-find-hydroxychloroquin-success-rate-91-urge-arizona-maybe-make 91% benefit] | ||
Zeile 5: | Zeile 16: | ||
*[https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf+html on safety, trial] | *[https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf+html on safety, trial] | ||
*[https://www.nejm.org/doi/full/10.1056/NEJMoa2012410?query=C19&cid=DM91569_NEJM_Registered_Users_and_InActive&bid=193180241 Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19] ''substance is useless.'' | *[https://www.nejm.org/doi/full/10.1056/NEJMoa2012410?query=C19&cid=DM91569_NEJM_Registered_Users_and_InActive&bid=193180241 Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19] ''substance is useless.'' | ||
+ | {{ttp|p=32437765|t=2020. Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19.|pdf=|usr=009}} | ||
{{tp|p=32232419|t=ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know |pdf=|usr=}} | {{tp|p=32232419|t=ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know |pdf=|usr=}} | ||
{{tp|p=32227189|t=ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 |pdf=|usr=}} | {{tp|p=32227189|t=ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19 |pdf=|usr=}} | ||
+ | {{ttp|p=32533263|t=2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.|pdf=|usr=008}} | ||
{{tp|p=32147496|t=2020. Of chloroquine and COVID-19 |pdf=|usr=}} | {{tp|p=32147496|t=2020. Of chloroquine and COVID-19 |pdf=|usr=}} | ||
{{tp|p=32074550|t=2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies |pdf=|usr=}} | {{tp|p=32074550|t=2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies |pdf=|usr=}} | ||
+ | {{tp|p=32496938|t=2020. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.|pdf=|usr=007}} | ||
{{tp|p=32321905|t=2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database |pdf=|usr=}} | {{tp|p=32321905|t=2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database |pdf=|usr=}} | ||
{{tp|p=32281583|t=2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32281583|t=2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | ||
Zeile 84: | Zeile 98: | ||
{{tp|p=32380315|t=ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}} | {{tp|p=32380315|t=ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}} | ||
{{tp|p=32348551|t=2020. Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data |pdf=|usr=}} | {{tp|p=32348551|t=2020. Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data |pdf=|usr=}} | ||
− | + | {{tp|p=32297988|t=2020. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis |pdf=|usr=}} | |
{{tp|p=32173110|t=2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 |pdf=|usr=}} | {{tp|p=32173110|t=2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 |pdf=|usr=}} | ||
− | + | {{tp|p=32347894|t=2020. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm |pdf=|usr=}} | |
− | + | {{tp|p=32236562|t=2020. Treating COVID-19 with Chloroquine |pdf=|usr=}} | |
{{tp|p=32333649|t=2020. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene |pdf=|usr=}} | {{tp|p=32333649|t=2020. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene |pdf=|usr=}} | ||
+ | {{tp|p=32379955|t=ä. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 |pdf=|usr=}} | ||
+ | {{tp|p=32285489|t=2020. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity |pdf=|usr=}} | ||
+ | {{tp|p=17806092|t=2008. Ferrocene Conjugates of Chloroquine and other Antimalarials: the Development of Ferroquine, a New Antimalarial |pdf=|usr=}} | ||
+ | {{tp|p=32164085|t=2020. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia |pdf=|usr=}} | ||
+ | {{ttp|p=32313209|t=ä. Chloroquine reduces Th17 cell differentiation by stimulating T-bet expression in T cells |pdf=|usr=}} | ||
+ | {{tp|p=C7162107|t=2020. Chloroquin gegen Corona?|pdf=|usr=}} | ||
+ | {{tp|p=C7197234|t=2020. Safety concerns with higher dosage chloroquine in COVID-19 patients |pdf=|usr=}} | ||
+ | {{tp|p=C7197245|t=2020. Antimalarial use in COVID-19 patients requires close monitoring |pdf=|usr=}} | ||
+ | {{tp|p=32167254|t=2020. Epidemie de coronavirus et polemique sur la chloroquine |pdf=|usr=}} | ||
+ | {{tp|p=32270942|t=2020. Covid-19, dans les brouillards francais de l'hydroxychloroquine |pdf=|usr=}} | ||
+ | {{tp|p=32301315|t=2020. Covid-19, dans les brouillards de l'hydroxychloroquine (2) |pdf=|usr=}} | ||
+ | {{tp|p=32381323|t=ä. Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury |pdf=|usr=}} | ||
+ | {{ttp|p=32298965|t=2020. Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate |pdf=|usr=}} | ||
+ | {{ttp|p=32380291|t=ä. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019 |pdf=|usr=}} | ||
+ | {{tp|p=32294495|t=ä. Chloroquine as a prophylactic agent against COVID-19?|pdf=|usr=}} | ||
+ | {{tp|p=C7184982|t=ä. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given |pdf=|usr=}} | ||
+ | {{ttp|p=32389720|t=ä. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin |pdf=|usr=}} | ||
+ | {{tp|p=32402766|t=2020. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection |pdf=|usr=}} | ||
+ | {{tp|p=32451138|t=ä. ...surveillance ophtalmologique ...hydroxychloroquine e... |pdf=|usr=}} | ||
+ | {{tp|p=32408070|t=2020. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win todays battle against COVID-19?|pdf=|usr=}} | ||
+ | {{tp|p=32386744|t=ä. Uso de antipaludicos (antimalarials)...|pdf=|usr=}} | ||
+ | {{tp|p=24773578|t=2014. Chloroquine interferes with dengue?2 virus replication in U937 cells |pdf=|usr=}} | ||
+ | {{tp|p=32409150|t=ä. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic |pdf=|usr=}} | ||
+ | {{tp|p=32286537|t=ä. Hydroxychloroquine: small effects in mild disease |pdf=|usr=}} | ||
+ | {{tp|p=32418730|t=ä. ?Off-label? use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers |pdf=|usr=}} | ||
+ | {{tp|p=32331804|t=ä. Hydroxychloroquine and ?off-label? utilization in the treatment of oral conditions |pdf=|usr=}} | ||
+ | {{ttp|p=28596841|t=2017. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases |pdf=|usr=}} | ||
+ | {{tp|p=32387409|t=ä. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France |pdf=|usr=}} | ||
+ | {{tp|p=32387694|t=ä. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review |pdf=|usr=}} | ||
+ | {{tp|p=32442941|t=2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.|pdf=|usr=007}} | ||
+ | {{tp|p=32458599|t=2020. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].|pdf=|usr=007}} | ||
+ | {{tp|p=32075365|t=2020. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].|pdf=|usr=007}} | ||
+ | {{tp|p=32498009|t=2020. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.|pdf=|usr=007}} | ||
+ | {{tp|p=32500556|t=2020. Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection.|pdf=|usr=007}} | ||
+ | {{tp|p=32474476|t=2020. Risk of using hydroxychloroquine as a treatment of COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32432527|t=2020. Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.|pdf=|usr=007}} | ||
+ | {{tp|p=32380930|t=2020. Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32435791|t=2020. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.|pdf=|usr=007}} | ||
+ | {{tp|p=32237918|t=2020. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.|pdf=|usr=007}} | ||
+ | {{tp|p=32303497|t=2020. Chloroquine and COVID-19 - a potential game changer?|pdf=|usr=007}} | ||
+ | {{tp|p=32321722|t=2020. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.|pdf=|usr=007}} | ||
+ | {{tp|p=32317316|t=2020. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?|pdf=|usr=007}} | ||
+ | {{tp|p=32317315|t=2020. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?|pdf=|usr=007}} | ||
+ | {{tp|p=32327429|t=2020. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.|pdf=|usr=007}} | ||
+ | {{tp|p=32295788|t=2020. Does hydroxychloroquine prevent the transmission of COVID-19?|pdf=|usr=007}} | ||
+ | {{tp|p=32295786|t=2020. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.|pdf=|usr=007}} | ||
+ | {{tp|p=32345618|t=2020. Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.|pdf=|usr=007}} | ||
+ | {{tp|p=32474576|t=2020. Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter?|pdf=|usr=007}} | ||
+ | {{tp|p=32501756|t=2020. Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32267732|t=2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.|pdf=|usr=007}} | ||
+ | {{tp|p=32415690|t=2020. Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.|pdf=|usr=007}} | ||
+ | {{tp|p=32436730|t=2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.|pdf=|usr=007}} | ||
+ | {{tp|p=32347743|t=2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.|pdf=|usr=007}} | ||
+ | {{tp|p=32430461|t=2020. Lack of efficacy of hydroxychloroquine in covid-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32503805|t=2020. Covid-19: Hydroxychloroquine was ineffective as postexposure prophylaxis, study finds.|pdf=|usr=007}} | ||
+ | {{tp|p=32487664|t=2020. Covid-19: 146 researchers raise concerns over chloroquine study that halted WHO trial.|pdf=|usr=007}} | ||
+ | {{tp|p=32269046|t=2020. Chloroquine and hydroxychloroquine in covid-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32469265|t=2020. Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.|pdf=|usr=007}} | ||
+ | {{tp|p=32438459|t=2020. Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.|pdf=|usr=007}} | ||
+ | {{tp|p=32473020|t=2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.|pdf=|usr=007}} | ||
+ | {{tp|p=32457980|t=2020. Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.|pdf=|usr=007}} | ||
+ | {{tp|p=32474918|t=2020. An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC) - Protocol publication.|pdf=|usr=007}} | ||
+ | {{tp|p=32324363|t=2020. [A szerzett hosszu-QT-szindroma veszelye a koronavirus-jarvany idejen. Fokuszban a hidroxiklorokin]|pdf=|usr=007}} | ||
+ | {{tp|p=32458488|t=2020. Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.|pdf=|usr=007}} | ||
+ | {{tp|p=32434282|t=2020. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?|pdf=|usr=007}} | ||
+ | {{tp|p=32448039|t=2020. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.|pdf=|usr=007}} | ||
+ | {{tp|p=32295814|t=2020. Hydroxychloroquine and covid-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32496926|t=2020. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32488217|t=2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.|pdf=|usr=007}} | ||
+ | {{tp|p=32496442|t=2020. Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?|pdf=|usr=007}} | ||
+ | {{tp|p=32490532|t=2020. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.|pdf=|usr=007}} | ||
+ | {{tp|p=32492298|t=2020. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.|pdf=|usr=007}} | ||
+ | {{tp|p=32492293|t=2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32479900|t=2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32281213|t=2020. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).|pdf=|usr=008}} | ||
+ | {{tp|p=32473921|t=2020. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.|pdf=|usr=008}} | ||
+ | {{tp|p=32439366|t=2020. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.|pdf=|usr=008}} | ||
+ | {{tp|p=32450198|t=2020. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.|pdf=|usr=008}} | ||
+ | {{tp|p=32405156|t=2020. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.|pdf=|usr=008}} | ||
+ | {{tp|p=32514594|t=2020. Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.|pdf=|usr=008}} | ||
+ | {{tp|p=32474851|t=2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32393448|t=2020. The ICMR bulletin on targeted hydroxychloroquine prophylaxis for Covid-19: Need to interpret with caution.|pdf=|usr=008}} | ||
+ | {{tp|p=32412404|t=2020. Outpatient hydroxychloroquine prescribing at a large academic health system during the COVID-19 pandemic.|pdf=|usr=008}} | ||
+ | {{tp|p=32470627|t=2020. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias.|pdf=|usr=008}} | ||
+ | {{tp|p=32407884|t=2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.|pdf=|usr=008}} | ||
+ | {{tp|p=32438018|t=2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.|pdf=|usr=008}} | ||
+ | {{tp|p=32535142|t=2020. Behavior of the PR Interval with Increasing Heart Rate in Patients with COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32400382|t=2020. [Brug af hydroxychloroquin til COVID-19].|pdf=|usr=007}} | ||
+ | {{tp|p=32400380|t=2020. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].|pdf=|usr=007}} | ||
+ | {{tp|p=32391667|t=2020. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].|pdf=|usr=007}} | ||
+ | {{tp|p=32402475|t=2020. Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data.|pdf=|usr=007}} | ||
+ | {{tp|p=32348059|t=2020. COVID-19, dans les brouillards de l'hydroxychloroquine (4).|pdf=|usr=007}} | ||
+ | {{tp|p=32320161|t=2020. Covid-19, dans les brouillards de l'hydroxychloroquine (3).|pdf=|usr=007}} | ||
+ | {{tp|p=32525093|t=2020. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32393664|t=2020. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.|pdf=|usr=007}} | ||
+ | {{tp|p=32451353|t=2020. Evidence of Protective Effect of Hydroxychloroquine on COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32474406|t=2020. The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.|pdf=|usr=007}} | ||
+ | {{tp|p=32463348|t=2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.|pdf=|usr=007}} | ||
+ | {{tp|p=32463308|t=2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?|pdf=|usr=007}} | ||
+ | {{tp|p=32496241|t=2020. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?|pdf=|usr=007}} | ||
+ | {{tp|p=32361760|t=2020. Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.|pdf=|usr=008}} | ||
+ | {{tp|p=32442699|t=2020. Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.|pdf=|usr=008}} | ||
+ | {{tp|p=32439468|t=2020. Dermatologic manifestations of hydroxychloroquine therapy: a closer look at the nails.|pdf=|usr=008}} | ||
+ | {{tp|p=32360856|t=2020. Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatologic and rheumatologic patients already under treatment.|pdf=|usr=008}} | ||
+ | {{tp|p=32348824|t=2020. Response to: "Risks of hydroxychloroquine use for COVID-19 prophylaxis".|pdf=|usr=008}} | ||
+ | {{tp|p=32407770|t=2020. COVID-19, Clinical Trials and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.|pdf=|usr=008}} | ||
+ | {{tp|p=32401405|t=2020. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.|pdf=|usr=008}} | ||
+ | {{tp|p=32474031|t=2020. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.|pdf=|usr=008}} | ||
+ | {{tp|p=32417904|t=2020. COVID-19 infection also occurs in patients taking hydroxychloroquine.|pdf=|usr=008}} | ||
+ | {{tp|p=32425199|t=2020. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.|pdf=|usr=008}} | ||
+ | {{ttp|p=32390140|t=2020. Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine.|pdf=|usr=008}} | ||
+ | {{tp|p=32359203|t=2020. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32517786|t=2020. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.|pdf=|usr=008}} | ||
+ | {{tp|p=32451259|t=2020. Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed.|pdf=|usr=008}} | ||
+ | {{tp|p=32439074|t=2020. COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?|pdf=|usr=008}} | ||
+ | {{tp|p=32449091|t=2020. Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.|pdf=|usr=008}} | ||
+ | {{tp|p=32422063|t=2020. Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?|pdf=|usr=008}} | ||
+ | {{tp|p=32383430|t=2020. Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with Novel Coronavirus Disease (COVID-19) Treated with Hydroxychloroquine.|pdf=|usr=008}} | ||
+ | {{tp|p=32314698|t=2020. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32475347|t=2020. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.|pdf=|usr=008}} | ||
+ | {{tp|p=32331979|t=2020. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.|pdf=|usr=008}} | ||
+ | {{tp|p=32525706|t=2020. The status surrounding chloroquine and other drugs as potential anti-infective agents for COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32531808|t=2020. Impact of disease on plasma and lung exposure of chloroquine, hydroxy-chloroquine and azithromycin: application of PBPK modelling.|pdf=|usr=008}} | ||
+ | {{tp|p=32520683|t=2020. Review on the clinical pharmacology of hydroxychloroquine sulfate for the treatment of COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32424028|t=2020. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?|pdf=|usr=008}} | ||
+ | {{tp|p=32424027|t=2020. Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre et al.|pdf=|usr=008}} | ||
+ | {{tp|p=32241791|t=2020. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.|pdf=|usr=008}} | ||
+ | {{tp|p=32519281|t=2020. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.|pdf=|usr=008}} | ||
+ | {{tp|p=32415419|t=2020. Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?|pdf=|usr=008}} | ||
+ | {{tp|p=32459529|t=2020. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.|pdf=|usr=008}} | ||
+ | {{ttp|p=32514696|t=2020. Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic.|pdf=|usr=008}} | ||
+ | {{tp|p=32418181|t=2020. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.|pdf=|usr=008}} | ||
+ | {{tp|p=32405664|t=2020. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.|pdf=|usr=008}} | ||
+ | {{tp|p=32401368|t=2020. Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32534369|t=2020. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.|pdf=|usr=008}} | ||
+ | {{tp|p=32362051|t=2020. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.|pdf=|usr=008}} | ||
+ | {{tp|p=32401410|t=2020. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.|pdf=|usr=008}} | ||
+ | {{tp|p=32253799|t=2020. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.|pdf=|usr=008}} | ||
+ | {{tp|p=32373993|t=2020. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32356580|t=2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.|pdf=|usr=008}} | ||
+ | {{tp|p=32495580|t=2020. [Pharmacovigilance study on drug-induced cardiac injury during treatment of COVID-19].|pdf=|usr=008}} | ||
+ | {{tp|p=32426364|t=2020. Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32391371|t=2020. SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.|pdf=|usr=008}} | ||
+ | {{tp|p=32391370|t=2020. The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity.|pdf=|usr=008}} | ||
+ | {{tp|p=32350928|t=2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32495148|t=2020. A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.|pdf=|usr=008}} | ||
+ | {{tp|p=32324284|t=2020. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.|pdf=|usr=008}} | ||
+ | {{tp|p=32417708|t=2020. "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis."|pdf=|usr=008}} | ||
+ | {{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}} | ||
+ | {{tp|p=32385749|t=2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.|pdf=|usr=008}} | ||
+ | {{tp|p=32392282|t=2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.|pdf=|usr=009}} | ||
+ | {{tp|p=32450109|t=2020. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?|pdf=|usr=009}} | ||
+ | {{tp|p=32418894|t=2020. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.|pdf=|usr=009}} | ||
+ | {{tp|p=32533592|t=2020. Pharmacist's perspective on HCQ treatment of COVID-19.|pdf=|usr=009}} | ||
+ | {{tp|p=32460458|t=2020. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.|pdf=|usr=009}} | ||
+ | {{tp|p=32350818|t=2020. Chloroquine-induced QTc prolongation in COVID-19 patients.|pdf=|usr=009}} | ||
+ | {{tp|p=32425245|t=2020. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.|pdf=|usr=009}} | ||
+ | {{tp|p=32430286|t=2020. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?|pdf=|usr=009}} | ||
+ | {{tp|p=32394513|t=2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.|pdf=|usr=009}} | ||
+ | {{tp|p=32395001|t=2020. Evidencia viva como respuesta a las controversias en el uso de antimalaricos en COVID-19.|pdf=|usr=009}} | ||
+ | {{tp|p=32528194|t=2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.|pdf=|usr=009}} | ||
+ | {{tp|p=32501367|t=2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.|pdf=|usr=009}} | ||
+ | {{tp|p=32418114|t=2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.|pdf=|usr=009}} | ||
+ | {{tp|p=32551892|t=2020. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.|pdf=|usr=010}} | ||
+ | {{tp|p=32485391|t=2020. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?|pdf=|usr=009}} | ||
+ | {{tp|p=32360423|t=2020. Malaria prophylaxis approach during COVID-19 pandemic.|pdf=|usr=009}} | ||
+ | {{tp|p=32473812|t=2020. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.|pdf=|usr=009}} | ||
+ | {{tp|p=32418732|t=2020. Chloroquine and hydroxychloroquine during pregnancy: What do we know?|pdf=|usr=009}} | ||
+ | {{tp|p=32457932|t=2020. Chloroquine, hydroxychloroquine and COVID-19.|pdf=|usr=009}} | ||
+ | {{tp|p=32557011|t=2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.|pdf=|usr=010}} | ||
+ | {{tp|p=32542893|t=2020. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.|pdf=|usr=010}} | ||
+ | {{tp|p=32554525|t=2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.|pdf=|usr=010}} | ||
+ | {{tp|p=32565195|t=2020. Chloroquine cardiac effects and toxicity.A short update.|pdf=|usr=010}} | ||
+ | {{tp|p=32556143|t=2020. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital.|pdf=|usr=010}} | ||
+ | {{tp|p=32540958|t=2020. Hydroxychloroquine for covid-19: the end of the line?|pdf=|usr=010}} | ||
+ | {{tp|p=32588427|t=2020. QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection.|pdf=|usr=010}} | ||
+ | {{tp|p=32552642|t=2020. Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19.|pdf=|usr=010}} | ||
+ | {{tp|p=32592507|t=2020. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.|pdf=|usr=010}} | ||
+ | {{tp|p=32588188|t=2020. Comment on "Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?"|pdf=|usr=010}} | ||
+ | {{tp|p=32567262|t=2020. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.|pdf=|usr=010}} | ||
+ | {{tp|p=32558210|t=2020. Clearance of chloroquine and hydroxychloroquine by the Seraph(R) 100 Microbind(R) Affinity blood filter - approved for the treatment of COVID-19 patients.|pdf=|usr=010}} | ||
+ | {{ttp|p=32579059|t=2020. Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets.|pdf=|usr=010}} | ||
+ | {{ttp|p=32571115|t=2020. Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.|pdf=|usr=010}} | ||
+ | {{tp|p=32564047|t=2020. Chloroquine in controlling biological infections.|pdf=|usr=010}} | ||
+ | {{tp|p=32323646|t=2020. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.|pdf=|usr=011}} | ||
+ | {{tp|p=32571633|t=2020. Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.|pdf=|usr=011}} | ||
+ | {{tp|p=32603983|t=2020. Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic.|pdf=|usr=011}} | ||
+ | {{tp|p=32409561|t=2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.|pdf=|usr=011}} | ||
+ | {{tp|p=32409486|t=2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.|pdf=|usr=011}} | ||
+ | {{tp|p=32350872|t=2020. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?|pdf=|usr=011}} | ||
+ | {{tp|p=32562278|t=2020. Novel Approach for Low-Dose Pulmonary Delivery of Hydroxychloroquine in COVID-19.|pdf=|usr=011}} | ||
+ | {{tp|p=32427154|t=2020. Hydroxychloroquine-based treatments in the CoViD-19 pandemic.|pdf=|usr=011}} | ||
+ | {{tp|p=32428074|t=2020. Chloroquine and hydroxychloroquine repositioning in times of COVID-19 pandemics, all that glitters is not gold.|pdf=|usr=011}} | ||
+ | {{tp|p=32600860|t=2020. Chloroquine and COVID-19: A western medical and scientific drift?|pdf=|usr=011}} | ||
+ | {{tp|p=32610165|t=2020. Effects of Hydroxychloroquine Treatment on QT Interval.|pdf=|usr=011}} | ||
+ | {{ttp|p=32601063|t=2020. Covid-19: Oxford team begins vaccine trials in Brazil and South Africa to determine efficacy.|pdf=|usr=011}} '''least regulated zones biggest negroe populations''' | ||
+ | {{tp|p=32559820|t=2020. Model informed dosing of Hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and Gaps.|pdf=|usr=011}} | ||
+ | {{tp|p=32602956|t=2020. The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question.|pdf=|usr=011}} | ||
+ | {{tp|p=32468425|t=2020. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).|pdf=|usr=011}} | ||
+ | {{tp|p=32392332|t=2020. Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics.|pdf=|usr=011}} | ||
+ | {{tp|p=32470568|t=2020. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.|pdf=|usr=011}} | ||
+ | {{tp|p=32422406|t=2020. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=011}} | ||
+ | {{tp|p=32384908|t=2020. Chloroquine for COVID-19: rationale, facts, hopes.|pdf=|usr=011}} | ||
+ | {{tp|p=32268005|t=2020. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.|pdf=|usr=011}} | ||
+ | {{tp|p=32401962|t=2020. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?|pdf=|usr=011}} | ||
+ | {{tp|p=32575065|t=2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.|pdf=|usr=011}} | ||
+ | {{tp|p=32285930|t=2020. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.|pdf=|usr=011}} | ||
+ | {{tp|p=32495226|t=2020. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?|pdf=|usr=011}} | ||
+ | {{tp|p=32348544|t=2020. Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data": Data-Driven Dosing Recommendations are Urgently Needed for Hydroxychloroquine in COVID-19 Patients: Response to Letter to the Editor.|pdf=|usr=011}} | ||
+ | {{tp|p=32344449|t=2020. Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.|pdf=|usr=011}} | ||
+ | {{tp|p=32320477|t=2020. Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation.|pdf=|usr=011}} | ||
+ | {{tp|p=32607690|t=2020. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.|pdf=|usr=011}} | ||
+ | {{tp|p=32559589|t=2020. Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy.|pdf=|usr=011}} | ||
+ | {{tp|p=32574312|t=2020. Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.|pdf=|usr=011}} | ||
+ | {{tp|p=32553587|t=2020. COVID-19 and hydroxychloroquine: Is the wonder drug failing?|pdf=|usr=011}} | ||
+ | {{tp|p=32549293|t=2020. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.|pdf=|usr=011}} | ||
+ | {{tp|p=32593867|t=2020. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.|pdf=|usr=011}} | ||
+ | {{tp|p=32330312|t=2020. Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India?|pdf=|usr=011}} | ||
+ | {{tp|p=32330276|t=2020. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.|pdf=|usr=011}} | ||
+ | {{tp|p=32411941|t=2020. When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?|pdf=|usr=011}} | ||
+ | {{tp|p=32562480|t=2020. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.|pdf=|usr=011}} | ||
+ | {{tp|p=32536565|t=2020. Living evidence in response to controversies about the use of antimalarials in COVID-19.|pdf=|usr=011}} | ||
+ | {{tp|p=32540396|t=2020. Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.|pdf=|usr=011}} | ||
+ | {{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=010}} | ||
+ | {{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}} | ||
+ | {{tp|p=32307721|t=2020. Extensive hard palate hyperpigmentation associated with chloroquine use.|pdf=|usr=015}} | ||
+ | {{tp|p=32375574|t=2020. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.|pdf=|usr=015}} | ||
+ | {{tp|p=32395638|t=2020. Chloroquine/Hydroxychloroquine Overdose.|pdf=|usr=015}} | ||
+ | {{tp|p=32427967|t=2020. Hydroxychloroquine hitting the headlines-retinal considerations.|pdf=|usr=015}} | ||
+ | {{tp|p=32519613|t=2020. Hydroxychloroquine and coronavirus disease 19.|pdf=|usr=019}} | ||
+ | {{tp|p=32537031|t=2020. Hochdosiertes Chloroquin bei COVID-19 gefahrlich.|pdf=|usr=015}} | ||
+ | {{tp|p=32560964|t=2020. Facts, not Fear: Safety of Hydroxychloroquine.|pdf=|usr=019}} | ||
+ | {{tp|p=32568274|t=2020. Hydroxychloroquine and coronavirus disease 2019.|pdf=|usr=019}} | ||
+ | {{tp|p=32587388|t=2020. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria.|pdf=|usr=015}} | ||
+ | {{tp|p=32591664|t=2020. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?|pdf=|usr=015}} | ||
+ | {{tp|p=32594451|t=2020. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.|pdf=|usr=015}} | ||
+ | {{tp|p=32606531|t=2020. Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?|pdf=|usr=015}} | ||
+ | {{tp|p=32610873|t=2020. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.|pdf=|usr=017}} | ||
+ | {{tp|p=32610879|t=2020. Hydroxychloroquine for COVID-19: What is our Current State of Knowledge?|pdf=|usr=017}} | ||
+ | {{tp|p=32616659|t=2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=012}} | ||
+ | {{tp|p=32617169|t=2020. Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.|pdf=|usr=015}} | ||
+ | {{tp|p=32623082|t=2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=012}} | ||
+ | {{tp|p=32624192|t=2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.|pdf=|usr=015}} | ||
+ | {{tp|p=32626630|t=2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.|pdf=|usr=015}} | ||
+ | {{tp|p=32631083|t=2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.|pdf=|usr=012}} | ||
+ | {{tp|p=32628049|t=2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.|pdf=|usr=012}} | ||
+ | {{tp|p=32629115|t=2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.|pdf=|usr=012}} | ||
+ | {{tp|p=32629139|t=2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".|pdf=|usr=012}} | ||
+ | {{tp|p=32629149|t=2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.|pdf=|usr=015}} | ||
+ | {{tp|p=32641296|t=2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.|pdf=|usr=012}} | ||
+ | {{tp|p=32629169|t=2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.|pdf=|usr=012}} | ||
+ | {{tp|p=32633733|t=2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.|pdf=|usr=012}} | ||
+ | {{tp|p=32634079|t=2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.|pdf=|usr=012}} | ||
+ | {{tp|p=32638884|t=2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?|pdf=|usr=012}} | ||
+ | {{tp|p=32639233|t=2020. Concentration-dependent mortality of chloroquine in overdose.|pdf=|usr=012}} | ||
+ | {{tp|p=32641037|t=2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.|pdf=|usr=012}} | ||
+ | {{tp|p=32641681|t=2020. Is hydroxychloroquine beneficial for COVID-19 patients?|pdf=|usr=012}} | ||
+ | {{tp|p=32641874|t=2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.|pdf=|usr=012}} | ||
+ | {{tp|p=32644224|t=2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.|pdf=|usr=012}} | ||
+ | {{tp|p=32645478|t=2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.|pdf=|usr=012}} | ||
+ | {{tp|p=32651040|t=2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.|pdf=|usr=014}} | ||
+ | {{tp|p=32651961|t=2020. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.|pdf=|usr=014}} | ||
+ | {{tp|p=32652194|t=2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.|pdf=|usr=014}} | ||
+ | {{tp|p=32654163|t=2020. First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.|pdf=|usr=017}} | ||
+ | {{tp|p=32657706|t=2020. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.|pdf=|usr=017}} | ||
+ | {{tp|p=32660993|t=2020. Safety, pharmacokinetics, and activity of high-dose ivermectin and chloroquine against the liver-stage of Plasmodium cynomolgi infection in Rhesus Macaques.|pdf=|usr=014}} | ||
+ | {{tp|p=32666027|t=2020. Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID?19).|pdf=|usr=015}} | ||
+ | {{tp|p=32667853|t=2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32668106|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32668107|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32668108|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32668109|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.|pdf=|usr=014}} | ||
+ | {{tp|p=32673059|t=2020. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.|pdf=|usr=014}} | ||
+ | {{tp|p=32673060|t=2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.|pdf=|usr=014}} | ||
+ | {{tp|p=32674126|t=2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.|pdf=|usr=014}} | ||
+ | {{tp|p=32674481|t=2020. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.|pdf=|usr=014}} | ||
+ | {{tp|p=32674928|t=2020. Review of: ?Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010 DOI:10.1016/j.ijantimicag.2020.105949.|pdf=|usr=015}} | ||
+ | {{tp|p=32674929|t=2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?|pdf=|usr=014}} | ||
+ | {{tp|p=32675039|t=?. Hydroxychloroquine and Potential Drug Interactions in Older Adults.|pdf=|usr=015}} | ||
+ | {{tp|p=32675166|t=2020. COVID-19, hydroxychloroquine and the eighth alternative.|pdf=|usr=014}} | ||
+ | {{tp|p=32677545|t=2020. Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study.|pdf=|usr=014}} | ||
+ | {{tp|p=32679150|t=2020. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.|pdf=|usr=014}} | ||
+ | {{tp|p=32682360|t=2020. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.|pdf=|usr=014}} | ||
+ | {{tp|p=32683212|t=2020. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32686260|t=2020. Insights in chloroquine action: perspectives and implications in Malaria and COVID-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32687630|t=2020. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.|pdf=|usr=014}} | ||
+ | {{tp|p=32687267|t=2020. Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns.|pdf=|usr=014}} | ||
+ | {{tp|p=32687645|t=2020. Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin.|pdf=|usr=014}} | ||
+ | {{tp|p=32687949|t=2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.|pdf=|usr=014}} | ||
+ | {{tp|p=32691896|t=2020. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.|pdf=|usr=014}} | ||
+ | {{tp|p=32693256|t=2020. Efficient degradation of chloroquine drug by electro-Fenton oxidation: Effects of operating conditions and degradation mechanism.|pdf=|usr=015}} | ||
+ | {{tp|p=32693652|t=2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.|pdf=|usr=014}} | ||
+ | {{tp|p=32694358|t=2020. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.|pdf=|usr=014}} | ||
+ | {{tp|p=32695719|t=2020. Hydroxychloroquine in Dermatology and Beyond: Recent Update.|pdf=|usr=018}} | ||
+ | {{tp|p=32696720|t=2020. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32698190|t=2020. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.|pdf=|usr=014}} | ||
+ | {{tp|p=32698191|t=2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.|pdf=|usr=014}} | ||
+ | {{tp|p=32701969|t=2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.|pdf=|usr=014}} | ||
+ | {{tp|p=32702733|t=?. A Novel RP-HPLC-DAD Method Development for Anti-Malarial and COVID-19 Hydroxy Chloroquine Sulfate Tablets and Profiling of In-Vitro Dissolution in Multimedia. .|pdf=|usr=015}} | ||
+ | {{tp|p=32702948|t=2020. Hydroxychloroquine-associated Thrombotic Thrombocytopenic Purpura.|pdf=|usr=018}} | ||
+ | {{tp|p=32705683|t=2020. High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection.|pdf=|usr=014}} | ||
+ | {{ttp|p=32706953|t=2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.|pdf=|usr=014}} | ||
+ | {{tp|p=32709544|t=2020. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.|pdf=|usr=014}} | ||
+ | {{tp|p=32711596|t=2020. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.|pdf=|usr=017}} | ||
+ | {{tp|p=32713288|t=2020. Chloroquine in fighting COVID-19: good, bad, or both?|pdf=|usr=014}} | ||
+ | {{tp|p=32713336|t=2020. Chloroquine as chemoprophylaxis for COVID-19: Will this work?|pdf=|usr=014}} | ||
+ | {{tp|p=32714335|t=2020. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.|pdf=|usr=014}} | ||
+ | {{tp|p=32723461|t=2020. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.|pdf=|usr=018}} | ||
+ | {{tp|p=32725866|t=2020. A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic.|pdf=|usr=017}} | ||
+ | {{tp|p=32730105|t=2020. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.|pdf=|usr=018}} | ||
+ | {{tp|p=32737109|t=2020. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al.|pdf=|usr=017}} | ||
+ | {{tp|p=32737111|t=2020. COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine.|pdf=|usr=017}} | ||
+ | {{tp|p=32738306|t=2020. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.|pdf=|usr=017}} | ||
+ | {{tp|p=32738307|t=2020. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32738483|t=2020. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32738491|t=2020. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?|pdf=|usr=017}} | ||
+ | {{tp|p=32738492|t=2020. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".|pdf=|usr=017}} | ||
+ | {{ttp|p=32738490|t=2020. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.|pdf=|usr=018}} | ||
+ | {{tp|p=32739472|t=2020. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32740070|t=2020. Chloroquine, Hydroxychloroquine, Retinal Toxicity, and COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32740072|t=2020. Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19).|pdf=|usr=017}} | ||
+ | {{tp|p=32740371|t=2020. A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients.|pdf=|usr=017}} | ||
+ | {{tp|p=32740441|t=2020. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemia.|pdf=|usr=017}} | ||
+ | {{tp|p=32740801|t=2020. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32740858|t=2020. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.|pdf=|usr=017}} | ||
+ | {{tp|p=32739134|t=2020. Tratamiento farmacologico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32742294|t=2020. Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus.|pdf=|usr=017}} | ||
+ | {{tp|p=32745629|t=2020. A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32749808|t=2020. Hydroxychloroquine en chloroquine bij COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32754147|t=2020. Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro.|pdf=|usr=017}} | ||
+ | {{tp|p=32754467|t=2020. COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings?|pdf=|usr=018}} | ||
+ | {{ttp|p=32757497|t=2020. Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication.|pdf=|usr=017}} | ||
+ | {{tp|p=32759263|t=2020. Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.|pdf=|usr=018}} | ||
+ | {{tp|p=32759257|t=2020. Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al.|pdf=|usr=017}} | ||
+ | {{tp|p=32759459|t=2020. Hydroxychloroquine is no miracle cure for covid-19 infection -imaging and clinical course in an elderly female.|pdf=|usr=018}} | ||
+ | {{ttp|p=32761451|t=2020. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs.|pdf=|usr=017}} | ||
+ | {{tp|p=32763298|t=2020. Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.|pdf=|usr=017}} | ||
+ | {{tp|p=32763357|t=2020. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.|pdf=|usr=018}} | ||
+ | {{tp|p=32763818|t=2020. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32766679|t=2020. Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.|pdf=|usr=017}} | ||
+ | {{tp|p=32767316|t=2020. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).|pdf=|usr=017}} | ||
+ | {{tp|p=32768698|t=2020. Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients.|pdf=|usr=018}} | ||
+ | {{tp|p=32769154|t=2020. Correspondence on 'Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef et al.|pdf=|usr=017}} | ||
+ | {{tp|p=32769149|t=2020. Response to: 'Correspondence on 'Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef et al' by Lo et al.|pdf=|usr=017}} | ||
+ | {{tp|p=32769401|t=2020. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?|pdf=|usr=018}} | ||
+ | {{tp|p=32770567|t=2020. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.|pdf=|usr=018}} | ||
+ | {{tp|p=32771630|t=2020. Comment on Arshad et al: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=017}} | ||
+ | {{tp|p=32772895|t=2020. Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study.|pdf=|usr=017}} | ||
+ | {{ttp|p=32773410|t=2020. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers.|pdf=|usr=017}} | ||
+ | {{tp|p=32773415|t=2020. Hydroxychloroquine for chemoprophylaxis in COVID-19: A case of motivated perception?|pdf=|usr=018}} | ||
+ | {{tp|p=32774508|t=2020. Chloroquine and COVID-19: Should We Care about Ototoxicity?|pdf=|usr=017}} | ||
+ | {{tp|p=32776298|t=2020. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.|pdf=|usr=018}} | ||
+ | {{tp|p=32776534|t=2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.|pdf=|usr=018}} | ||
+ | {{tp|p=32777263|t=2020. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.|pdf=|usr=018}} | ||
+ | {{tp|p=32777441|t=2020. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-COV-2 infection?|pdf=|usr=017}} | ||
+ | {{tp|p=32779755|t=2020. Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China.|pdf=|usr=017}} | ||
+ | {{ttp|p=32780229|t=2020. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.|pdf=|usr=017}} | ||
+ | {{tp|p=32780273|t=2020. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.|pdf=|usr=018}} | ||
+ | {{tp|p=32784192|t=2020. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.|pdf=|usr=018}} | ||
+ | {{tp|p=32786041|t=2020. Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir.|pdf=|usr=018}} | ||
+ | {{tp|p=32790733|t=2020. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.|pdf=|usr=018}} | ||
+ | {{tp|p=32802983|t=2020. Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin.|pdf=|usr=018}} | ||
+ | {{ttp|p=32808712|t=2020. Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials.|pdf=|usr=018}} | ||
+ | {{tp|p=32811798|t=2020. Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen.|pdf=|usr=018}} | ||
+ | {{tp|p=32812725|t=2020. Hydroxychloroquine-related Rash in COVID-19 Infected Patient.|pdf=|usr=018}} | ||
+ | {{tp|p=32814539|t=2020. Is ocular toxicity expected in chloroquine/hydroxychloroquine prescription as a therapeutic or prophylactic option in COVID-19?|pdf=|usr=018}} | ||
+ | {{tp|p=32819797|t=2020. Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out.|pdf=|usr=018}} | ||
+ | {{ttp|p=32821381|t=2020. Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.|pdf=|usr=018}} | ||
+ | {{ttp|p=32823144|t=2020. The host targeting effect of chloroquine in malaria.|pdf=|usr=018}} | ||
+ | {{ttp|p=32824072|t=2020. New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.|pdf=|usr=018}} | ||
+ | {{tp|p=32828135|t=2020. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.|pdf=|usr=019}} | ||
+ | {{tp|p=32828896|t=2020. A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Reunion Island.|pdf=|usr=018}} | ||
+ | {{tp|p=32833728|t=2020. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.|pdf=|usr=018}} | ||
+ | {{tp|p=32834063|t=2020. Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19.|pdf=|usr=019}} | ||
+ | {{tt{{tp|p=32837201|t=2020. Inefficacite et dangerosite potentielle de l'hydroxychloroquine pour traiter une infection par le coronavirus Sars-cov2.|pdf=|usr=018}} | ||
+ | {{tp|p=32835721|t=2020. Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment.|pdf=|usr=019}} | ||
+ | {{tp|p=32838043|t=2020. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32838355|t=2020. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32801224|t=2020. Optimal dosing & time: Issues to get hydroxychloroquine safety & efficacy against COVID-19/SARS-CoV-2.|pdf=|usr=018}} | ||
+ | {{tp|p=32839670|t=2020. Hydroxychloroquine is protective to the heart, not harmful: a systematic review.|pdf=|usr=018}} | ||
+ | {{tp|p=32844224|t=2020. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.|pdf=|usr=018}} | ||
+ | {{ttp|p=32849619|t=2020. Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus.|pdf=|usr=018}} | ||
+ | {{ttp|p=32849658|t=2020. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?|pdf=|usr=018}} | ||
+ | {{ttp|p=32849936|t=2020. Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=018}} | ||
+ | {{ttp|p=32850924|t=2020. Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis.|pdf=|usr=018}} | ||
+ | {{tp|p=32853033|t=2020. Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32853673|t=2020. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.|pdf=|usr=018}} | ||
+ | {{tp|p=32859477|t=2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.|pdf=|usr=018}} | ||
+ | {{tp|p=32860358|t=2020. Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?|pdf=|usr=018}} | ||
+ | {{ttp|p=32860962|t=2020. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.|pdf=|usr=019}} | ||
+ | {{tp|p=32861824|t=2020. The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32861965|t=2020. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.|pdf=|usr=018}} | ||
+ | {{ttp|p=32862840|t=2020. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.|pdf=|usr=018}} | ||
+ | {{tp|p=32863397|t=2020. Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach.|pdf=|usr=019}} | ||
+ | {{ttp|p=32864299|t=2020. Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2.|pdf=|usr=018}} | ||
+ | {{tp|p=32870539|t=2020. Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine.|pdf=|usr=018}} | ||
+ | {{tp|p=32872629|t=2020. Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19.|pdf=|usr=018}} | ||
+ | {{ttp|p=32876108|t=2020. The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19.|pdf=|usr=018}} | ||
+ | {{tp|p=32877501|t=2020. Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.|pdf=|usr=018}} | ||
+ | {{tp|p=32880032|t=2020. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.|pdf=|usr=018}} | ||
+ | {{tp|p=32881593|t=2020. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.|pdf=|usr=018}} | ||
+ | {{ttp|p=32881895|t=2020. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.|pdf=|usr=018}} | ||
+ | {{tp|p=32882888|t=2020. Zinc(II)-The Overlooked Eminence Grise of Chloroquine's Fight against COVID-19?|pdf=|usr=018}} | ||
+ | {{tp|p=32884603|t=2020. Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.|pdf=|usr=018}} | ||
+ | {{ttp|p=32885373|t=2020. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.|pdf=|usr=018}} | ||
+ | {{tp|p=32888840|t=2020. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics.|pdf=|usr=018}} | ||
+ | {{tp|p=32889105|t=2020. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".|pdf=|usr=018}} | ||
+ | {{ttp|p=32892293|t=2020. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.|pdf=|usr=019}} | ||
+ | {{tp|p=32893123|t=2020. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltration with nafamostat mesylate.|pdf=|usr=019}} | ||
+ | {{tp|p=32903552|t=2020. A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2.|pdf=|usr=019}} | ||
+ | {{tp|p=32908842|t=2020. Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander?|pdf=|usr=019}} | ||
+ | {{ttp|p=32910933|t=2020. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=32914465|t=2020. Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?|pdf=|usr=019}} | ||
+ | {{tp|p=32915766|t=2020. Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood.|pdf=|usr=020}} | ||
+ | {{tp|p=32920291|t=2020. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.|pdf=|usr=019}} | ||
+ | {{tp|p=32921099|t=2020. Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials.|pdf=|usr=020}} | ||
+ | {{tp|p=32921965|t=2020. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.|pdf=|usr=019}} | ||
+ | {{tp|p=32922210|t=2020. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?|pdf=|usr=019}} | ||
+ | {{tp|p=32923151|t=2020. Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.|pdf=|usr=019}} | ||
+ | {{tp|p=32926573|t=2020. Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=32929975|t=2020. Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients.|pdf=|usr=019}} | ||
+ | {{tp|p=32933365|t=2020. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.|pdf=|usr=019}} | ||
+ | {{tp|p=32935064|t=2020. Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?|pdf=|usr=019}} | ||
+ | {{tp|p=32936918|t=2020. COVID-19 & Hydroxychloroquine side-effects: Glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia.|pdf=|usr=019}} | ||
+ | {{ttp|p=32942793|t=2020. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.|pdf=|usr=019}} | ||
+ | {{tp|p=32942923|t=2020. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=32946004|t=2020. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.|pdf=|usr=019}} | ||
+ | {{ttp|p=32947043|t=2020. Chloroquine against malaria, cancers and viral diseases.|pdf=|usr=019}} | ||
+ | {{ttp|p=32947506|t=2020. Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in Treating COVID-19 Patients.|pdf=|usr=019}} | ||
+ | {{tp|p=32956851|t=2020. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.|pdf=|usr=019}} | ||
+ | {{tp|p=32960061|t=2020. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.|pdf=|usr=019}} | ||
+ | {{tp|p=32960100|t=2020. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.|pdf=|usr=019}} | ||
+ | {{tp|p=32961123|t=2020. Hydroxychloroquine early in pregnancy and risk of birth defects.|pdf=|usr=019}} | ||
+ | {{tp|p=32963091|t=2020. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.|pdf=|usr=019}} | ||
+ | {{tp|p=32967165|t=2020. Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=32968208|t=2020. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.|pdf=|usr=019}} | ||
+ | {{tp|p=32968954|t=2020. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.|pdf=|usr=019}} | ||
+ | {{tp|p=32973504|t=2020. The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine.|pdf=|usr=019}} | ||
+ | {{tp|p=32980540|t=2020. Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence.|pdf=|usr=019}} | ||
+ | {{tp|p=32981388|t=2020. Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course.|pdf=|usr=019}} | ||
+ | {{tp|p=32982538|t=2020. Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation.|pdf=|usr=019}} | ||
+ | {{tp|p=32983403|t=2020. Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations.|pdf=|usr=019}} | ||
+ | {{tp|p=32983541|t=2020. First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2.|pdf=|usr=020}} | ||
+ | {{ttp|p=32983702|t=2020. A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=32987193|t=2020. Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.|pdf=|usr=019}} | ||
+ | {{tp|p=33007473|t=2020. Re: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.|pdf=|usr=019}} | ||
+ | {{tp|p=32997237|t=2020. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients.|pdf=|usr=019}} | ||
+ | {{tp|p=33001138|t=2020. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.|pdf=|usr=019}} | ||
+ | {{tp|p=33007039|t=2020. Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model.|pdf=|usr=019}} | ||
+ | {{tp|p=33007453|t=2020. Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?|pdf=|usr=019}} | ||
+ | {{tp|p=33007454|t=2020. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.|pdf=|usr=019}} | ||
+ | {{tp|p=33008280|t=2020. Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection.|pdf=|usr=019}} | ||
+ | {{ttp|p=33017762|t=2020. Chloroquine commonly induces hormetic dose responses.|pdf=|usr=019}} | ||
+ | {{tp|p=33017904|t=2020. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=33020690|t=2020. Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.|pdf=|usr=019}} | ||
+ | {{tp|p=33028485|t=2020. Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.|pdf=|usr=021}} | ||
+ | {{tp|p=33029911|t=2020. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.|pdf=|usr=020}} | ||
+ | {{tp|p=33031488|t=2020. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33031652|t=2020. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33033459|t=2020. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?|pdf=|usr=020}} | ||
+ | {{ttp|p=33042552|t=2020. Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review.|pdf=|usr=020}} | ||
+ | {{tp|p=33044019|t=2020. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.|pdf=|usr=020}} | ||
+ | {{tp|p=33048372|t=2020. Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.|pdf=|usr=020}} | ||
+ | {{tp|p=33050869|t=2020. COVID-19 And Type 2 Diabetes Mellitus: Hydroxychloroquine May Be The Holy Grail.|pdf=|usr=020}} | ||
+ | {{tp|p=33052313|t=2020. Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools.|pdf=|usr=020}} | ||
+ | {{tp|p=33054978|t=2020. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.|pdf=|usr=020}} | ||
+ | {{tp|p=33058086|t=2020. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study.|pdf=|usr=020}} | ||
+ | {{tp|p=33062720|t=2020. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.|pdf=|usr=020}} | ||
+ | {{tp|p=33068425|t=2020. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial.|pdf=|usr=020}} | ||
+ | {{tp|p=33068758|t=2020. Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine.|pdf=|usr=020}} | ||
+ | {{ttp|p=33071096|t=2020. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians.|pdf=|usr=020}} | ||
+ | {{tp|p=33075259|t=2020. In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19; trial stopped for futility.|pdf=|usr=020}} | ||
+ | {{tp|p=33075513|t=2020. Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend() SF PH4 (dry).|pdf=|usr=020}} | ||
+ | {{tp|p=33075525|t=2020. Hydroxychloroquine safety outcome with an approved therapeutic protocol for COVID-19 outpatients in Saudi Arabia.|pdf=|usr=020}} | ||
+ | {{ttp|p=33075529|t=2020. The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?|pdf=|usr=020}} | ||
+ | {{tp|p=33078372|t=2020. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.|pdf=|usr=020}} | ||
+ | {{tp|p=33082342|t=2020. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.|pdf=|usr=020}} | ||
+ | {{ttp|p=33082891|t=2020. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33085507|t=2020. Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33087414|t=2020. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.|pdf=|usr=020}} | ||
+ | {{ttp|p=33088574|t=2020. Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world.|pdf=|usr=020}} | ||
+ | {{tp|p=33089306|t=2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.|pdf=|usr=020}} | ||
+ | {{tp|p=33091817|t=2020. Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.|pdf=|usr=020}} | ||
+ | {{ttp|p=33095083|t=2021. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.|pdf=|usr=020}} | ||
+ | {{ttp|p=33100674|t=2020. Therapeutic status of hydroxychloroquine in COVID-19: A review.|pdf=|usr=020}} | ||
+ | {{tp|p=33110944|t=2020. A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.|pdf=|usr=020}} | ||
+ | {{tp|p=33111169|t=2020. No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33113232|t=2020. Generalized exanthema due to hydroxychloroquine as a popular drug during COVID-19 prophylaxis.|pdf=|usr=020}} | ||
+ | {{ttp|p=33115235|t=2020. Hydroxychloroquine Exhibits a Strong Complex Interaction with DNA: Unraveling the Mechanism of Action.|pdf=|usr=020}} | ||
+ | {{tp|p=33115586|t=2020. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.|pdf=|usr=020}} | ||
+ | {{tp|p=33116907|t=2020. Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?|pdf=|usr=020}} | ||
+ | {{tp|p=33117441|t=2020. Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice.|pdf=|usr=020}} | ||
+ | {{tp|p=33122096|t=2020. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.|pdf=|usr=020}} | ||
+ | {{tp|p=33122936|t=2020. Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.|pdf=|usr=020}} | ||
+ | {{tp|p=33127218|t=2020. Does hydroxychloroquine reduce mortality for COVID-19?|pdf=|usr=020}} | ||
+ | {{tp|p=33127507|t=2020. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.|pdf=|usr=020}} | ||
+ | {{tp|p=33130195|t=2020. Why we should be more careful using hydroxychloroquine in influenza season?|pdf=|usr=020}} | ||
+ | {{tp|p=33131749|t=2020. Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice.|pdf=|usr=020}} | ||
+ | {{tp|p=33132004|t=2020. Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness.|pdf=|usr=020}} | ||
+ | {{tp|p=33134417|t=2020. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.|pdf=|usr=020}} | ||
+ | {{tp|p=33135382|t=2020. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.|pdf=|usr=020}} | ||
+ | {{tp|p=33152333|t=2020. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead.|pdf=|usr=020}} | ||
+ | {{ttp|p=33154234|t=2020. Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33154723|t=2020. Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33156564|t=2020. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.|pdf=|usr=020}} | ||
+ | {{tp|p=33159196|t=2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.|pdf=|usr=020}} | ||
+ | {{tp|p=33163329|t=2020. Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review.|pdf=|usr=023}} | ||
+ | {{tp|p=33163976|t=2020. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.|pdf=|usr=020}} | ||
+ | {{tp|p=33165216|t=2020. Development and validation of a simple and rapid UHPLC-MS/MS method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic.|pdf=|usr=020}} | ||
+ | {{tp|p=33165621|t=2020. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.|pdf=|usr=020}} | ||
+ | {{tp|p=33166179|t=2020. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.|pdf=|usr=020}} | ||
+ | {{tp|p=33166647|t=2020. Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response.|pdf=|usr=020}} | ||
+ | {{tp|p=33166694|t=2020. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.|pdf=|usr=020}} | ||
+ | {{tp|p=33166894|t=2020. A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.|pdf=|usr=020}} | ||
+ | {{ttp|p=33167571|t=2020. Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.|pdf=|usr=020}} | ||
+ | {{tp|p=33176880|t=2020. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M(Pro) inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).|pdf=|usr=020}} | ||
+ | {{tp|p=33179983|t=2020. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33183501|t=2020. Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.|pdf=|usr=021}} | ||
+ | {{tp|p=33188451|t=2020. Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.|pdf=|usr=020}} | ||
+ | {{tp|p=33191905|t=2020. A case report of hydroxychloroquine-induced auditory and visual hallucination.|pdf=|usr=022}} | ||
+ | {{tp|p=33192503|t=2020. Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19.|pdf=|usr=020}} | ||
+ | {{tp|p=33194150|t=2020. "Hemolysis, or not Hemolysis, that is the Question". Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency.|pdf=|usr=020}} | ||
+ | {{tp|p=33200683|t=2020. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.|pdf=|usr=022}} | ||
+ | {{ttp|p=33202656|t=2020. Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.|pdf=|usr=021}} | ||
+ | {{ttp|p=33204210|t=2020. Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety.|pdf=|usr=021}} | ||
+ | {{tp|p=33204427|t=2020. Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers.|pdf=|usr=021}} | ||
+ | {{tp|p=33204764|t=2020. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19.|pdf=|usr=021}} | ||
+ | {{tp|p=33206554|t=2020. Chloroquine/hydroxycloroquine and COVID-19: need to know more about.|pdf=|usr=022}} | ||
+ | {{tp|p=33210858|t=2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.|pdf=|usr=021}} | ||
+ | {{tp|p=33231925|t=2020. Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial.|pdf=|usr=021}} | ||
+ | {{tp|p=33236590|t=2020. Hydroxychloroquine-related Rash in COVID-19 Infected Patient.|pdf=|usr=022}} | ||
+ | {{tp|p=33239282|t=2020. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.|pdf=|usr=022}} | ||
+ | {{ttp|p=33244901|t=2020. Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.|pdf=|usr=022}} | ||
+ | {{ttp|p=33247380|t=2020. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial.|pdf=|usr=021}} | ||
+ | {{tp|p=33250604|t=2021. DFT and molecular docking study of chloroquine derivatives as antiviral to coronavirus COVID-19.|pdf=|usr=021}} | ||
+ | {{tp|p=33251500|t=2020. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.|pdf=|usr=022}} | ||
+ | {{ttp|p=33256141|t=2020. Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial.|pdf=|usr=022}} | ||
+ | {{tp|p=33259916|t=2020. Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19.|pdf=|usr=022}} | ||
+ | {{tp|p=33259917|t=2020. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.|pdf=|usr=022}} | ||
+ | {{tp|p=33264337|t=2020. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).|pdf=|usr=022}} | ||
+ | {{tp|p=33270137|t=2020. Dose-response effects of hydroxychloroquine on prophylaxis against SARS-CoV-2 / COVID-19 infection.|pdf=|usr=022}} | ||
+ | {{tp|p=33278866|t=2020. Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia.|pdf=|usr=022}} | ||
+ | {{ttp|p=33283842|t=2020. The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=022}} | ||
+ | {{tp|p=33284679|t=2020. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.|pdf=|usr=022}} | ||
+ | {{tp|p=33284685|t=2020. Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection.|pdf=|usr=022}} | ||
+ | {{tp|p=33292107|t=2020. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.|pdf=|usr=022}} | ||
+ | {{tp|p=33310025|t=?. Comparison of hospital treatment strategy or of actually received treatment with hydroxychloroquine in COVID-19??.|pdf=|usr=023}} | ||
+ | {{tp|p=33310109|t=?. Response to ?Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients?.|pdf=|usr=023}} | ||
+ | {{ttp|p=33310480|t=2021. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.|pdf=|usr=023}} | ||
+ | {{tp|p=C7238396|t=?. Within a large healthcare system the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy.|pdf=|usr=015}} | ||
+ | {{tp|p=C7240261|t=?. Spectral domain optical coherence tomography?based prevalence of hydroxychloroquine maculopathy in Indian patients on hydroxychloroquine therapy: A utopia of underdiagnosis.|pdf=|usr=015}} | ||
+ | {{tp|p=C7252145|t=?. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.|pdf=|usr=015}} | ||
+ | {{tp|p=C7266611|t=2020. Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies.|pdf=|usr=015}} | ||
+ | {{tp|p=C7279711|t=?. Letter to the Editor: Acharya Prafulla Chandra Ray Hydroxychloroquine and COVID-19.|pdf=|usr=015}} | ||
+ | {{tp|p=C7313782|t=?. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.|pdf=|usr=015}} | ||
+ | {{tp|p=C7315151|t=2020. Hydroxychloroquine retinal toxicity: The bull s eye in the human eye.|pdf=|usr=015}} | ||
+ | {{tp|p=C7323248|t=?. Hydroxychloroquine treatment in COVID?19: a descriptive observational analysis of 30 cases from a single center in Wuhan China.|pdf=|usr=015}} | ||
+ | {{tp|p=C7334972|t=?. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence?.|pdf=|usr=015}} | ||
+ | {{tp|p=C7339103|t=2020. Hydroxychloroquine ? An Antimalarial to Fight COVID-19?|pdf=|usr=015}} | ||
+ | {{tp|p=C7341047|t=?. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of COVID-19: Psychopharmacological Interactions and Neuropsychiatric Sequelae.|pdf=|usr=015}} | ||
+ | {{tp|p=C7342085|t=?. Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.|pdf=|usr=015}} | ||
+ | {{tp|p=C7345387|t=?. Chloroquine kills hair cells in zebrafish lateral line and murine cochlear cultures: Implications for ototoxicity.|pdf=|usr=015}} | ||
+ | {{tp|p=C7348103|t=2020. Hydroxychloroquine: Acute haemolysis that lead to acute renal failure: case report.|pdf=|usr=015}} | ||
+ | {{tp|p=C7354765|t=?. Hydroxychloroquine-associated Hypoglycemia in Hemodialysis Patients with COVID-19.|pdf=|usr=015}} | ||
+ | {{tp|p=C7598544|t=2020. 153 Do Hydroxychloroquine Disease-Modifying Antirheumatic Agents or Steroids Serve to Prevent COVID-19 Infection?|pdf=|usr=023}} | ||
+ | {{tp|p=C7598546|t=?. Utility of hypertonic saline and diazepam in COVID-19-related hydroxychloroquine toxicity.|pdf=|usr=023}} | ||
+ | {{tp|p=C7648225|t=2020. Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports.|pdf=|usr=023}} | ||
+ | {{tp|p=C7661812|t=2020. Hydroxychloroquine: Neutropenia maculopapular rash and urinary tract infection following an off label use: 3 case reports.|pdf=|usr=023}} | ||
+ | {{tp|p=C7661828|t=2020. Azithromycin/hydroxychloroquine: Methemoglobinemia following off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7661829|t=2020. Azithromycin/hydroxychloroquine: Cardiac arrest following off-label use: 2 case reports.|pdf=|usr=023}} | ||
+ | {{tp|p=C7677448|t=2020. Hydroxychloroquine/tocilizumab: Cytomegalovirus enterocolitis and hypovolaemic-shock following off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7692423|t=2020. Hydroxychloroquine: Various toxicities secondary to off label use: 3 case reports.|pdf=|usr=023}} | ||
+ | {{tp|p=C7705928|t=?. Can Hydroxychloroquine Cause G6PD-Related Hemolysis? A Case Study.|pdf=|usr=023}} | ||
+ | {{tp|p=C7723760|t=?. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective non-randomized trial.|pdf=|usr=023}} | ||
+ | {{tp|p=C7726299|t=2020. Azithromycin/hydroxychloroquine: Elevated liver enzymes following off label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7728511|t=2020. Hydroxychloroquine: Acute intravascular haemolytic anaemia following off-label use: case report.|pdf=|usr=023}} | ||
+ | {{tp|p=C7728522|t=2020. PRAC review confirms chloroquine- and hydroxychloroquine-related AEs.|pdf=|usr=023}} | ||
+ | {{tp|p=32773424|t=2020. Effect of quantitative real-time RT-PCR reaction sensitivity in determining the efficacy of HCQ prophylaxis for COVID-19.|pdf=|usr=019}} | ||
+ | {{tp|p=C7351559|t=?. Can HCQ Be Considered a ?Safe Weapon? for COVID-19 in the Indian Population?|pdf=|usr=015}} |
Aktuelle Version vom 11. April 2021, 15:55 Uhr
PHA retargeted compounds |
POL HCQ ethics |
Hydroxychloroquine and QTc |
Azithromycin |
includes azithromycin + hcq regimes
20436917 2010. Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication |
- check retina status; monitor rhythm known toxicity
- 91% benefit
- approval russia
- scale up production
- on safety, trial
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 substance is useless.
32437765 2020. Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19. |
32232419 ä. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
32227189 ä. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19
32533263 2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. |
32147496 2020. Of chloroquine and COVID-19
32074550 2020. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
32496938 2020. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
32321905 2020. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
32281583 2020. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
32265182 2020. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
32194981 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
32371558 2020. Hydroxychloroquine use in the COVID-19 patient
32150618 ä. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
32211771 ä. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?
32211764 ä. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?
32255489 ä. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients
32306288 ä. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
32269021 2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection
32345336 2020. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2
32351851 ä. A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine
32340837 ä. Hydroxychloroquine in Covid-19: Does the end justify the means?
32247211 2020. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries
32321878 2020. Is GSK3beta a molecular target of chloroquine treatment against COVID-19?
32371138 ä. Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19
32266694 ä. Chloroquine for COVID-19 Infection
32373183 2020. Chloroquine and hydroxychloroquine in the context of COVID-19
32338155 2020. Rheumotologitsts view on the use of hydroxychloroquine to treat COVID-19
32347923 ä. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety
32212513 2020. The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 COVID-19 and Its Research Progress in Forensic Toxicology
32363145 ä. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine
32363144 ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin
32341910 2020. SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis
32278018 ä. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society
32335560 2020. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials
32205204 ä. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
32171740 ä. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
32070753 2020. Chloroquine for the 2019 novel coronavirus SARS-CoV-2
C7152897 ä. Chloroquine as prophylactic agent against COVID-19?
32194152 ä. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
32145363 2020. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
32363157 2020. Chloroquine: Can it be a Novel Drug for COVID-19
32283236 ä. Does hydroxychloroquine combat COVID-19? A timeline of evidence
32330546 ä. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin
32281268 2020. G6PD and chloroquine: Selecting the treatment against SARS?CoV?2?
32356863 ä. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
32356858 ä. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit
32330277 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
32339248 2020. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial
32363144 ä. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin
32251731 ä. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
32283237 ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
32283123 ä. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment
32196083 ä. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
32236561 ä. Combating COVID-19 with Chloroquine
32281481 2020. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review
32365215 2020. Behandling med 4-aminokinoliner vid covid-19 kan ge allvarliga biverkningar
32278373 2020. Regulators split on antimalarials for COVID-19
32359771 ä. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
32304640 ä. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base
32368738 2020. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology
32311322 ä. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
32311324 ä. Hydroxychloroquine prophylaxis for COVID-19 contacts in India
32322402 2020. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19
32316270 2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help
32231349 2020. Chloroquine in COVID-19: the evidence
32217166 2020. Chloroquine and COVID-19, where do we stand??
32240719 ä. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
32350818 ä. Chloroquine-induced QTc prolongation in COVID-19 patients
32344177 2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
32305500 ä. Chloroquine paradox may cause more damage than help fight COVID-19
32322397 2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
32327397 ä. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine
32363212 ä. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
32292817 2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
32267301 ä. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes
32347963 2020. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19
32247518 2020. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
32349115 ä. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19 |
32289548 2020. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
32247925 ä. Repurposing antimalarials and other drugs for COVID-19
32380315 ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
32348551 2020. Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data
32297988 2020. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis
32173110 2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
32347894 2020. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm
32236562 2020. Treating COVID-19 with Chloroquine
32333649 2020. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene
32379955 ä. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
32285489 2020. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity
17806092 2008. Ferrocene Conjugates of Chloroquine and other Antimalarials: the Development of Ferroquine, a New Antimalarial
32164085 2020. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia
32313209 ä. Chloroquine reduces Th17 cell differentiation by stimulating T-bet expression in T cells |
C7162107 2020. Chloroquin gegen Corona?
C7197234 2020. Safety concerns with higher dosage chloroquine in COVID-19 patients
C7197245 2020. Antimalarial use in COVID-19 patients requires close monitoring
32167254 2020. Epidemie de coronavirus et polemique sur la chloroquine
32270942 2020. Covid-19, dans les brouillards francais de l'hydroxychloroquine
32301315 2020. Covid-19, dans les brouillards de l'hydroxychloroquine (2)
32381323 ä. Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury
32298965 2020. Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate |
32380291 ä. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019 |
32294495 ä. Chloroquine as a prophylactic agent against COVID-19?
C7184982 ä. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given
32389720 ä. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin |
32402766 2020. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection
32451138 ä. ...surveillance ophtalmologique ...hydroxychloroquine e...
32408070 2020. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win todays battle against COVID-19?
32386744 ä. Uso de antipaludicos (antimalarials)...
24773578 2014. Chloroquine interferes with dengue?2 virus replication in U937 cells
32409150 ä. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic
32286537 ä. Hydroxychloroquine: small effects in mild disease
32418730 ä. ?Off-label? use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
32331804 ä. Hydroxychloroquine and ?off-label? utilization in the treatment of oral conditions
28596841 2017. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases |
32387409 ä. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
32387694 ä. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review
32442941 2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.
32458599 2020. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].
32075365 2020. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
32498009 2020. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
32500556 2020. Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection.
32474476 2020. Risk of using hydroxychloroquine as a treatment of COVID-19.
32432527 2020. Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.
32380930 2020. Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19.
32435791 2020. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.
32237918 2020. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.
32303497 2020. Chloroquine and COVID-19 - a potential game changer?
32321722 2020. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.
32317316 2020. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
32317315 2020. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
32327429 2020. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
32295788 2020. Does hydroxychloroquine prevent the transmission of COVID-19?
32295786 2020. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.
32345618 2020. Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.
32474576 2020. Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter?
32501756 2020. Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.
32267732 2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
32415690 2020. Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.
32436730 2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
32347743 2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
32430461 2020. Lack of efficacy of hydroxychloroquine in covid-19.
32503805 2020. Covid-19: Hydroxychloroquine was ineffective as postexposure prophylaxis, study finds.
32487664 2020. Covid-19: 146 researchers raise concerns over chloroquine study that halted WHO trial.
32269046 2020. Chloroquine and hydroxychloroquine in covid-19.
32469265 2020. Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.
32438459 2020. Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.
32473020 2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
32457980 2020. Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.
32474918 2020. An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC) - Protocol publication.
32324363 2020. [A szerzett hosszu-QT-szindroma veszelye a koronavirus-jarvany idejen. Fokuszban a hidroxiklorokin]
32458488 2020. Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.
32434282 2020. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
32448039 2020. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.
32295814 2020. Hydroxychloroquine and covid-19.
32496926 2020. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
32488217 2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
32496442 2020. Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?
32490532 2020. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
32492298 2020. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.
32492293 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32479900 2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.
32281213 2020. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
32473921 2020. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.
32439366 2020. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.
32450198 2020. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
32405156 2020. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
32514594 2020. Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.
32474851 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19.
32393448 2020. The ICMR bulletin on targeted hydroxychloroquine prophylaxis for Covid-19: Need to interpret with caution.
32412404 2020. Outpatient hydroxychloroquine prescribing at a large academic health system during the COVID-19 pandemic.
32470627 2020. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias.
32407884 2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
32438018 2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.
32535142 2020. Behavior of the PR Interval with Increasing Heart Rate in Patients with COVID-19.
32400382 2020. [Brug af hydroxychloroquin til COVID-19].
32400380 2020. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
32391667 2020. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
32402475 2020. Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data.
32348059 2020. COVID-19, dans les brouillards de l'hydroxychloroquine (4).
32320161 2020. Covid-19, dans les brouillards de l'hydroxychloroquine (3).
32525093 2020. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
32393664 2020. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.
32451353 2020. Evidence of Protective Effect of Hydroxychloroquine on COVID-19.
32474406 2020. The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.
32463348 2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
32463308 2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
32496241 2020. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
32361760 2020. Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
32442699 2020. Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.
32439468 2020. Dermatologic manifestations of hydroxychloroquine therapy: a closer look at the nails.
32360856 2020. Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatologic and rheumatologic patients already under treatment.
32348824 2020. Response to: "Risks of hydroxychloroquine use for COVID-19 prophylaxis".
32407770 2020. COVID-19, Clinical Trials and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.
32401405 2020. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.
32474031 2020. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.
32417904 2020. COVID-19 infection also occurs in patients taking hydroxychloroquine.
32425199 2020. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
32390140 2020. Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine. |
32359203 2020. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.
32517786 2020. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
32451259 2020. Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed.
32439074 2020. COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
32449091 2020. Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.
32422063 2020. Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?
32383430 2020. Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with Novel Coronavirus Disease (COVID-19) Treated with Hydroxychloroquine.
32314698 2020. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19.
32475347 2020. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.
32331979 2020. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
32525706 2020. The status surrounding chloroquine and other drugs as potential anti-infective agents for COVID-19.
32531808 2020. Impact of disease on plasma and lung exposure of chloroquine, hydroxy-chloroquine and azithromycin: application of PBPK modelling.
32520683 2020. Review on the clinical pharmacology of hydroxychloroquine sulfate for the treatment of COVID-19.
32424028 2020. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
32424027 2020. Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre et al.
32241791 2020. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.
32519281 2020. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.
32415419 2020. Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?
32459529 2020. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
32514696 2020. Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. |
32418181 2020. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
32405664 2020. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
32401368 2020. Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.
32534369 2020. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
32362051 2020. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.
32401410 2020. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
32253799 2020. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
32373993 2020. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
32356580 2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
32495580 2020. [Pharmacovigilance study on drug-induced cardiac injury during treatment of COVID-19].
32426364 2020. Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19.
32391371 2020. SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.
32391370 2020. The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity.
32350928 2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19.
32495148 2020. A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
32324284 2020. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.
32417708 2020. "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis."
32485061 2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.
32385749 2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
32392282 2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
32450109 2020. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?
32418894 2020. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
32533592 2020. Pharmacist's perspective on HCQ treatment of COVID-19.
32460458 2020. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
32350818 2020. Chloroquine-induced QTc prolongation in COVID-19 patients.
32425245 2020. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia cientifica concluyente.
32430286 2020. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
32394513 2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.
32395001 2020. Evidencia viva como respuesta a las controversias en el uso de antimalaricos en COVID-19.
32528194 2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.
32501367 2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.
32418114 2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
32551892 2020. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
32485391 2020. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?
32360423 2020. Malaria prophylaxis approach during COVID-19 pandemic.
32473812 2020. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.
32418732 2020. Chloroquine and hydroxychloroquine during pregnancy: What do we know?
32457932 2020. Chloroquine, hydroxychloroquine and COVID-19.
32557011 2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.
32542893 2020. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.
32554525 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
32565195 2020. Chloroquine cardiac effects and toxicity.A short update.
32556143 2020. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital.
32540958 2020. Hydroxychloroquine for covid-19: the end of the line?
32588427 2020. QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection.
32552642 2020. Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19.
32592507 2020. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.
32588188 2020. Comment on "Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?"
32567262 2020. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
32558210 2020. Clearance of chloroquine and hydroxychloroquine by the Seraph(R) 100 Microbind(R) Affinity blood filter - approved for the treatment of COVID-19 patients.
32579059 2020. Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. |
32571115 2020. Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice. |
32564047 2020. Chloroquine in controlling biological infections.
32323646 2020. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
32571633 2020. Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.
32603983 2020. Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic.
32409561 2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
32409486 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
32350872 2020. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
32562278 2020. Novel Approach for Low-Dose Pulmonary Delivery of Hydroxychloroquine in COVID-19.
32427154 2020. Hydroxychloroquine-based treatments in the CoViD-19 pandemic.
32428074 2020. Chloroquine and hydroxychloroquine repositioning in times of COVID-19 pandemics, all that glitters is not gold.
32600860 2020. Chloroquine and COVID-19: A western medical and scientific drift?
32610165 2020. Effects of Hydroxychloroquine Treatment on QT Interval.
32601063 2020. Covid-19: Oxford team begins vaccine trials in Brazil and South Africa to determine efficacy. |
32559820 2020. Model informed dosing of Hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and Gaps.
32602956 2020. The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question.
32468425 2020. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
32392332 2020. Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics.
32470568 2020. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
32422406 2020. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
32384908 2020. Chloroquine for COVID-19: rationale, facts, hopes.
32268005 2020. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.
32401962 2020. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
32575065 2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
32285930 2020. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
32495226 2020. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
32348544 2020. Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data": Data-Driven Dosing Recommendations are Urgently Needed for Hydroxychloroquine in COVID-19 Patients: Response to Letter to the Editor.
32344449 2020. Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness.
32320477 2020. Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation.
32607690 2020. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.
32559589 2020. Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy.
32574312 2020. Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.
32553587 2020. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
32549293 2020. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.
32593867 2020. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
32330312 2020. Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India?
32330276 2020. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019.
32411941 2020. When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?
32562480 2020. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.
32536565 2020. Living evidence in response to controversies about the use of antimalarials in COVID-19.
32540396 2020. Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.
32561608 2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.
32523144 2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.
32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
32307721 2020. Extensive hard palate hyperpigmentation associated with chloroquine use.
32375574 2020. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.
32395638 2020. Chloroquine/Hydroxychloroquine Overdose.
32427967 2020. Hydroxychloroquine hitting the headlines-retinal considerations.
32519613 2020. Hydroxychloroquine and coronavirus disease 19.
32537031 2020. Hochdosiertes Chloroquin bei COVID-19 gefahrlich.
32560964 2020. Facts, not Fear: Safety of Hydroxychloroquine.
32568274 2020. Hydroxychloroquine and coronavirus disease 2019.
32587388 2020. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria.
32591664 2020. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?
32594451 2020. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
32606531 2020. Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?
32610873 2020. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.
32610879 2020. Hydroxychloroquine for COVID-19: What is our Current State of Knowledge?
32616659 2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.
32617169 2020. Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.
32623082 2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
32624192 2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
32626630 2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.
32631083 2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
32628049 2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.
32629115 2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.
32629139 2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
32629149 2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
32641296 2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
32629169 2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
32633733 2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.
32634079 2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
32638884 2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
32639233 2020. Concentration-dependent mortality of chloroquine in overdose.
32641037 2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.
32641681 2020. Is hydroxychloroquine beneficial for COVID-19 patients?
32641874 2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.
32644224 2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
32645478 2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.
32651040 2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.
32651961 2020. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.
32652194 2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.
32654163 2020. First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.
32657706 2020. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
32660993 2020. Safety, pharmacokinetics, and activity of high-dose ivermectin and chloroquine against the liver-stage of Plasmodium cynomolgi infection in Rhesus Macaques.
32666027 2020. Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID?19).
32667853 2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
32668106 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32668107 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32668108 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32668109 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.
32673059 2020. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.
32673060 2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.
32674126 2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.
32674481 2020. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.
32674928 2020. Review of: ?Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010 DOI:10.1016/j.ijantimicag.2020.105949.
32674929 2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
32675039 ?. Hydroxychloroquine and Potential Drug Interactions in Older Adults.
32675166 2020. COVID-19, hydroxychloroquine and the eighth alternative.
32677545 2020. Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study.
32679150 2020. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
32682360 2020. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.
32683212 2020. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
32686260 2020. Insights in chloroquine action: perspectives and implications in Malaria and COVID-19.
32687630 2020. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
32687267 2020. Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns.
32687645 2020. Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin.
32687949 2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.
32691896 2020. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.
32693256 2020. Efficient degradation of chloroquine drug by electro-Fenton oxidation: Effects of operating conditions and degradation mechanism.
32693652 2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
32694358 2020. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.
32695719 2020. Hydroxychloroquine in Dermatology and Beyond: Recent Update.
32696720 2020. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.
32698190 2020. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
32698191 2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
32701969 2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
32702733 ?. A Novel RP-HPLC-DAD Method Development for Anti-Malarial and COVID-19 Hydroxy Chloroquine Sulfate Tablets and Profiling of In-Vitro Dissolution in Multimedia. .
32702948 2020. Hydroxychloroquine-associated Thrombotic Thrombocytopenic Purpura.
32705683 2020. High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection.
32706953 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. |
32709544 2020. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
32711596 2020. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
32713288 2020. Chloroquine in fighting COVID-19: good, bad, or both?
32713336 2020. Chloroquine as chemoprophylaxis for COVID-19: Will this work?
32714335 2020. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.
32723461 2020. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
32725866 2020. A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic.
32730105 2020. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
32737109 2020. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al.
32737111 2020. COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine.
32738306 2020. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
32738307 2020. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
32738483 2020. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.
32738491 2020. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
32738492 2020. Problems with the analysis in "Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19".
32738490 2020. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials. |
32739472 2020. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.
32740070 2020. Chloroquine, Hydroxychloroquine, Retinal Toxicity, and COVID-19.
32740072 2020. Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19).
32740371 2020. A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients.
32740441 2020. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemia.
32740801 2020. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
32740858 2020. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse.
32739134 2020. Tratamiento farmacologico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19.
32742294 2020. Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus.
32745629 2020. A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19.
32749808 2020. Hydroxychloroquine en chloroquine bij COVID-19.
32754147 2020. Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro.
32754467 2020. COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings?
32757497 2020. Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication. |
32759263 2020. Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.
32759257 2020. Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al.
32759459 2020. Hydroxychloroquine is no miracle cure for covid-19 infection -imaging and clinical course in an elderly female.
32761451 2020. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. |
32763298 2020. Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.
32763357 2020. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.
32763818 2020. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
32766679 2020. Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
32767316 2020. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).
32768698 2020. Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients.
32769154 2020. Correspondence on 'Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef et al.
32769149 2020. Response to: 'Correspondence on 'Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist' by Graef et al' by Lo et al.
32769401 2020. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?
32770567 2020. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study.
32771630 2020. Comment on Arshad et al: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
32772895 2020. Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study.
32773410 2020. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers. |
32773415 2020. Hydroxychloroquine for chemoprophylaxis in COVID-19: A case of motivated perception?
32774508 2020. Chloroquine and COVID-19: Should We Care about Ototoxicity?
32776298 2020. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
32776534 2020. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study.
32777263 2020. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results.
32777441 2020. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-COV-2 infection?
32779755 2020. Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China.
32780229 2020. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. |
32780273 2020. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.
32784192 2020. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
32786041 2020. Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir.
32790733 2020. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
32802983 2020. Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin.
32808712 2020. Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials. |
32811798 2020. Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen.
32812725 2020. Hydroxychloroquine-related Rash in COVID-19 Infected Patient.
32814539 2020. Is ocular toxicity expected in chloroquine/hydroxychloroquine prescription as a therapeutic or prophylactic option in COVID-19?
32819797 2020. Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out.
32821381 2020. Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. |
32823144 2020. The host targeting effect of chloroquine in malaria. |
32824072 2020. New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine. |
32828135 2020. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.
32828896 2020. A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Reunion Island.
32833728 2020. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.
32834063 2020. Quantum mechanical simulation of Chloroquine drug interaction with C60 fullerene for treatment of COVID-19.
{{tt
32837201 2020. Inefficacite et dangerosite potentielle de l'hydroxychloroquine pour traiter une infection par le coronavirus Sars-cov2.
32835721 2020. Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment.
32838043 2020. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
32838355 2020. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.
32801224 2020. Optimal dosing & time: Issues to get hydroxychloroquine safety & efficacy against COVID-19/SARS-CoV-2.
32839670 2020. Hydroxychloroquine is protective to the heart, not harmful: a systematic review.
32844224 2020. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.
32849619 2020. Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus. |
32849658 2020. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin? |
32849936 2020. Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. |
32850924 2020. Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. |
32853033 2020. Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
32853673 2020. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.
32859477 2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
32860358 2020. Nanocarriers in the delivery of hydroxychloroquine to the respiratory system: An alternative to COVID-19?
32860962 2020. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. |
32861824 2020. The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19.
32861965 2020. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
32862840 2020. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. |
32863397 2020. Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach.
32864299 2020. Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. |
32870539 2020. Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine.
32872629 2020. Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19.
32876108 2020. The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19. |
32877501 2020. Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
32880032 2020. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
32881593 2020. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
32881895 2020. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. |
32882888 2020. Zinc(II)-The Overlooked Eminence Grise of Chloroquine's Fight against COVID-19?
32884603 2020. Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19.
32885373 2020. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. |
32888840 2020. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics.
32889105 2020. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
32892293 2020. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. |
32893123 2020. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltration with nafamostat mesylate.
32903552 2020. A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2.
32908842 2020. Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander?
32910933 2020. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. |
32914465 2020. Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?
32915766 2020. Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood.
32920291 2020. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.
32921099 2020. Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials.
32921965 2020. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.
32922210 2020. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
32923151 2020. Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
32926573 2020. Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19.
32929975 2020. Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients.
32933365 2020. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.
32935064 2020. Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?
32936918 2020. COVID-19 & Hydroxychloroquine side-effects: Glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia.
32942793 2020. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine. |
32942923 2020. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
32946004 2020. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
32947043 2020. Chloroquine against malaria, cancers and viral diseases. |
32947506 2020. Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in Treating COVID-19 Patients. |
32956851 2020. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.
32960061 2020. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
32960100 2020. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
32961123 2020. Hydroxychloroquine early in pregnancy and risk of birth defects.
32963091 2020. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
32967165 2020. Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19.
32968208 2020. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
32968954 2020. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
32973504 2020. The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine.
32980540 2020. Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence.
32981388 2020. Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course.
32982538 2020. Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation.
32983403 2020. Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations.
32983541 2020. First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2.
32983702 2020. A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19. |
32987193 2020. Re: 'Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.
33007473 2020. Re: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients' by Fiolet et al.
32997237 2020. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients.
33001138 2020. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
33007039 2020. Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model.
33007453 2020. Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?
33007454 2020. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.
33008280 2020. Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection.
33017762 2020. Chloroquine commonly induces hormetic dose responses. |
33017904 2020. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19.
33020690 2020. Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study.
33028485 2020. Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection.
33029911 2020. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.
33031488 2020. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.
33031652 2020. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
33033459 2020. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?
33042552 2020. Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. |
33044019 2020. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.
33048372 2020. Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.
33050869 2020. COVID-19 And Type 2 Diabetes Mellitus: Hydroxychloroquine May Be The Holy Grail.
33052313 2020. Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools.
33054978 2020. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
33058086 2020. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study.
33062720 2020. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.
33068425 2020. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial.
33068758 2020. Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine.
33071096 2020. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. |
33075259 2020. In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19; trial stopped for futility.
33075513 2020. Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend() SF PH4 (dry).
33075525 2020. Hydroxychloroquine safety outcome with an approved therapeutic protocol for COVID-19 outpatients in Saudi Arabia.
33075529 2020. The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment? |
33078372 2020. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
33082342 2020. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.
33082891 2020. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. |
33085507 2020. Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
33087414 2020. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
33088574 2020. Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. |
33089306 2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.
33091817 2020. Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.
33095083 2021. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. |
33100674 2020. Therapeutic status of hydroxychloroquine in COVID-19: A review. |
33110944 2020. A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.
33111169 2020. No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.
33113232 2020. Generalized exanthema due to hydroxychloroquine as a popular drug during COVID-19 prophylaxis.
33115235 2020. Hydroxychloroquine Exhibits a Strong Complex Interaction with DNA: Unraveling the Mechanism of Action. |
33115586 2020. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
33116907 2020. Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?
33117441 2020. Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice.
33122096 2020. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.
33122936 2020. Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.
33127218 2020. Does hydroxychloroquine reduce mortality for COVID-19?
33127507 2020. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
33130195 2020. Why we should be more careful using hydroxychloroquine in influenza season?
33131749 2020. Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice.
33132004 2020. Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness.
33134417 2020. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.
33135382 2020. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.
33152333 2020. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead.
33154234 2020. Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis. |
33154723 2020. Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis.
33156564 2020. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
33159196 2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.
33163329 2020. Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review.
33163976 2020. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.
33165216 2020. Development and validation of a simple and rapid UHPLC-MS/MS method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic.
33165621 2020. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
33166179 2020. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.
33166647 2020. Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response.
33166694 2020. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.
33166894 2020. A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.
33167571 2020. Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. |
33176880 2020. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M(Pro) inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
33179983 2020. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.
33183501 2020. Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.
33188451 2020. Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.
33191905 2020. A case report of hydroxychloroquine-induced auditory and visual hallucination.
33192503 2020. Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19.
33194150 2020. "Hemolysis, or not Hemolysis, that is the Question". Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency.
33200683 2020. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
33202656 2020. Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. |
33204210 2020. Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety. |
33204427 2020. Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers.
33204764 2020. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19.
33206554 2020. Chloroquine/hydroxycloroquine and COVID-19: need to know more about.
33210858 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
33231925 2020. Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial.
33236590 2020. Hydroxychloroquine-related Rash in COVID-19 Infected Patient.
33239282 2020. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
33244901 2020. Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials. |
33247380 2020. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. |
33250604 2021. DFT and molecular docking study of chloroquine derivatives as antiviral to coronavirus COVID-19.
33251500 2020. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.
33256141 2020. Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. |
33259916 2020. Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19.
33259917 2020. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.
33264337 2020. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).
33270137 2020. Dose-response effects of hydroxychloroquine on prophylaxis against SARS-CoV-2 / COVID-19 infection.
33278866 2020. Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia.
33283842 2020. The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. |
33284679 2020. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
33284685 2020. Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection.
33292107 2020. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.
33310025 ?. Comparison of hospital treatment strategy or of actually received treatment with hydroxychloroquine in COVID-19??.
33310109 ?. Response to ?Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients?.
33310480 2021. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. |
C7238396 ?. Within a large healthcare system the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy.
C7240261 ?. Spectral domain optical coherence tomography?based prevalence of hydroxychloroquine maculopathy in Indian patients on hydroxychloroquine therapy: A utopia of underdiagnosis.
C7252145 ?. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.
C7266611 2020. Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies.
C7279711 ?. Letter to the Editor: Acharya Prafulla Chandra Ray Hydroxychloroquine and COVID-19.
C7313782 ?. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.
C7315151 2020. Hydroxychloroquine retinal toxicity: The bull s eye in the human eye.
C7323248 ?. Hydroxychloroquine treatment in COVID?19: a descriptive observational analysis of 30 cases from a single center in Wuhan China.
C7334972 ?. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence?.
C7339103 2020. Hydroxychloroquine ? An Antimalarial to Fight COVID-19?
C7341047 ?. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of COVID-19: Psychopharmacological Interactions and Neuropsychiatric Sequelae.
C7342085 ?. Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature.
C7345387 ?. Chloroquine kills hair cells in zebrafish lateral line and murine cochlear cultures: Implications for ototoxicity.
C7348103 2020. Hydroxychloroquine: Acute haemolysis that lead to acute renal failure: case report.
C7354765 ?. Hydroxychloroquine-associated Hypoglycemia in Hemodialysis Patients with COVID-19.
C7598544 2020. 153 Do Hydroxychloroquine Disease-Modifying Antirheumatic Agents or Steroids Serve to Prevent COVID-19 Infection?
C7598546 ?. Utility of hypertonic saline and diazepam in COVID-19-related hydroxychloroquine toxicity.
C7648225 2020. Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports.
C7661812 2020. Hydroxychloroquine: Neutropenia maculopapular rash and urinary tract infection following an off label use: 3 case reports.
C7661828 2020. Azithromycin/hydroxychloroquine: Methemoglobinemia following off-label use: case report.
C7661829 2020. Azithromycin/hydroxychloroquine: Cardiac arrest following off-label use: 2 case reports.
C7677448 2020. Hydroxychloroquine/tocilizumab: Cytomegalovirus enterocolitis and hypovolaemic-shock following off-label use: case report.
C7692423 2020. Hydroxychloroquine: Various toxicities secondary to off label use: 3 case reports.
C7705928 ?. Can Hydroxychloroquine Cause G6PD-Related Hemolysis? A Case Study.
C7723760 ?. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective non-randomized trial.
C7726299 2020. Azithromycin/hydroxychloroquine: Elevated liver enzymes following off label use: case report.
C7728511 2020. Hydroxychloroquine: Acute intravascular haemolytic anaemia following off-label use: case report.
C7728522 2020. PRAC review confirms chloroquine- and hydroxychloroquine-related AEs.
32773424 2020. Effect of quantitative real-time RT-PCR reaction sensitivity in determining the efficacy of HCQ prophylaxis for COVID-19.
C7351559 ?. Can HCQ Be Considered a ?Safe Weapon? for COVID-19 in the Indian Population?